Skin and Soft Tissue Substitutes - UHCprovider.com

1 skin and soft Tissue Substitutes Page 1 of 66 UnitedHealthcare Commercial Medical Policy Effective 07/01/2022 Proprietary Information of UnitedHealthcare. Copyright 2022 United HealthCare Services, Inc. UnitedHealthcare Commercial Medica l Policy skin and soft Tissue Substitutes Policy Number: 2022T0592N Effective Date: July 1, 2022 Instructions for Use Table of Contents Page Coverage Rationale .. 1 Definitions .. 3 Applicable Codes .. 4 Description of Services .. 7 Clinical 8 Food and Drug 59 References .. 59 Policy History/Revision Information .. 65 Instructions for 66 Coverage Rationale EpiFix or Grafix (GrafixPL, GrafixPRIME and GrafixPL PRIME) (Non-Injectable) EpiFix or Grafix is proven and medically necessary for treating diabetic foot ulcer when all of the following criteria are met: Adequate circulation to the affected extremity as indicated by one or more of the following.

2 O Pedal pulses palpable o Ankle-brachial index (ABI) between and o Dorsum transcutaneous oxygen test (TcPO2) 30 mm Hg within the last 60 days o Triphasic or biphasic Doppler arterial waveforms at the ankle of affected leg Optimal glucose control Glycated hemoglobin test (HgA1c) < 12% (within the last 90 days) Individual has a diagnosis of Type 1 or Type 2 diabetes Ulcer size 1 cm2 and < 25 cm2 Ulcer has failed to demonstrate Measurable Signs of Healing with at least 4 weeks of standard wound care which includes all of the following: o Application of dressings to maintain a moist wound environment o Debridement of necrotic Tissue , if present o Offloading Individual does not have active Charcot deformity or major structural abnormalities of the affected foot Individual does not have a known or suspected malignancy of the current ulcer being treated Standard wound care continues Ulcer being treated does not extend to tendon, muscle.

3 Capsule or bone EpiFix and Grafix Application Limitations EpiFix is limited to one application per week for up to 12 weeks Grafix is limited to one application per week for up to 12 weeks Due to insufficient evidence of efficacy, EpiFix and/or Grafix are unproven and not medically necessary for all other indications including but not limited to: EpiFix application more frequently than once a week or beyond 12 weeks Grafix application more frequently than once a week or beyond 12 weeks Related Commercial Policies Prolotherapy and Platelet Rich Plasma Therapies Breast Reconstruction Post Mastectomy and Poland Syndrome Community Plan Policy skin and soft Tissue Substitutes skin and soft Tissue Substitutes Page 2 of 66 UnitedHealthcare Commercial Medical Policy Effective 07/01/2022 Proprietary Information of UnitedHealthcare.

4 Copyright 2022 United HealthCare Services, Inc. TransCyte TransCyte is proven and medically necessary for treating surgically excised Full-Thickness Thermal Burn wounds and deep Partial-Thickness Thermal Burn wounds before autograft placement. TransCyte is unproven and not medically necessary for all other indications due to insufficient evidence of efficacy. Other skin and soft Tissue Substitutes The following skin and soft Tissue Substitutes are unproven and not medically necessary for any indication* due to insufficient evidence of efficacy: Affinity AlloGen AlloSkin AlloWrap Altiply Amnio Wound Amnio Wrap2 AmnioAMP-MP AmnioArmor AmnioBand AmnioBind AmnioCore Amniocyte Plus AMNIOEXCEL , AMNIOEXCEL Plus.

5 Or BioDExcel AmnioFix AMNIOMATRIX or BioDMatrix Amnio-Maxx or Amnio-Maxx Lite Amniorepair Amniotext Amniotext patch Amnion Bio AMNIPLY Apis Architect Artacent Cord Artacent Wound or Artacent AC ArthroFLEX Ascent AxoBioMembrane Axolotl Ambient or Axolotl Cryo Axolotl Graft or Axolotl DualGraft BellaCell HD bio-ConneKt BioDfence or BioDFence DryFlex Bioskin Bioskin Flow Biovance BioWound , BioWound Plus, or BioWound Xplus Cellesta or Cellesta Duo Cellesta Cord Cellesta Flowable Amnion CLARIX CLARIX FLO Cogenex (amniotic membrane and flowable amnion) Coll-e-Derm Conexa Corecyte Coretext or Protext CorMatrix Corplex Corplex p Cryo-Cord Cygnus matrix or Cygnus Cymetra Cytal DermACELL *, DermACELL AWM or DermACELL AWM Porous (see asterisked note below when DermACELL is used during breast reconstruction)

6 Dermacyte Derma-Gide DermaPure DermaSpan Dermavest or Plurivest Derm-Maxx Enverse EpiCord EpiFix , injectable Excellagen E-Z Derm FlowerAmnioFlo or FlowerFlo FlowerAmnioPatch or FlowerPatch FlowerDerm Fluid Flow Fluid GF GammaGraft Genesis Amniotic Membrane Grafix Core Guardian Helicoll hMatrix Human Health Factor 10 Amniotic Patch (HHF10-P) Hyalomatrix InnovaMatrix AC or Innovamatrix FS Integra Flowable Wound Matrix InteguPly Interfyl Keramatrix Kerasorb Kerecis Omega3 Keroxx skin and soft Tissue Substitutes Page 3 of 66 UnitedHealthcare Commercial Medical Policy Effective 07/01/2022 Proprietary Information of UnitedHealthcare.

7 Copyright 2022 United HealthCare Services, Inc. Matrion MatriStem Mediskin Membrane Graft Membrane Wrap MemoDerm Microlyte Matrix Mirragen Advanced Wound Matrix MIRODERM MLG-Complete MyOwn skin NeoPatch NEOX NEOX FLO Novachor Novafix Novafix DL NovoSorb SynPath NuDYN NuShield PalinGen Amniotic Tissue Allograft and PalinGen Flow products Polycyte PriMatrix Procenta ProgenaMatrix ProMatrX PuraPly , PuraPly AM, or PuraPly XT REGUaRD Relese Repriza Restorigin Restrata Revita Revitalon SkinTE STRATTICE Stravix or StravixPL Supra SDRM Suprathel Surederm Surfactor SurGraft SurgiCORD SurgiGRAFT SurgiGRAFT-DUAL Symphony Talymed TenSIX TheraGenesis TheraSkin Therion TranZgraft TruSkin Vendaje Vim WoundEx WoundEx Flow WoundFix , WoundFix Plus.

8 Or WoundFix Xplus XCelliStem Xcellerate XCM BIOLOGIC Tissue Matrix XWRAP Zenith Amniotic Membrane *Refer to the Coverage Determination Guideline titled Breast Reconstruction Post Mastectomy and Poland Syndrome for information about coverage for skin and soft Tissue Substitutes used during post mastectomy breast reconstruction procedures. Definitions Acellular Matrix: A Matrix that is derived from sources other than human skin . Acellular Matrices are the most frequently used skin substitute. Acellular Matrices are composed of allogeneic or xenogeneic derived collagen, membrane, or cellular remnants (Debels et al.)

9 , 2015; Ferreira et al., 2011; Nicholas et al., 2016; Vig et al., 2017). Allogeneic Matrix: A Matrix that is derived from human Tissue such as neonatal fibroblasts of the foreskin (Debels et al., 2015; Ferreira et al., 2011; Nicholas et al., 2016; Vig et al., 2017). Composite Matrix: A Matrix that is derived from human keratinocytes and fibroblasts supported by a scaffold of synthetic mesh or xenogeneic collagen. These Matrices contain active cellular components that continue to generate compounds and protein that may accelerate wound healing (Debels et al., 2015; Ferreira et al., 2011; Nicholas et al., 2016; Vig et al.

10 , 2017). Full-Thickness Thermal Burn (Third Degree Burn): A burn with destruction of all layers of the skin . These burns involve all of the epidermal and dermal layers, with varying amounts of the sub-cutaneous layer involvement (Gomez and Cancio, 2007). skin and soft Tissue Substitutes Page 4 of 66 UnitedHealthcare Commercial Medical Policy Effective 07/01/2022 Proprietary Information of UnitedHealthcare. Copyright 2022 United HealthCare Services, Inc. Human skin Allograft: An Allograft that is derived from donated human skin ( , cadavers) that has been processed to remove the cellular components (Debels et al.